ROCKVILLE, Md., June 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
Regenxbio has promoted Curran Simpson, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024.
REGENXBIO to Participate in Cantor Fitzgerald`s Virtual DMD and Other Dystrophy Days
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock
REGENXBIO Announces Proposed Public Offering of Common Stock
Regenxbio Announces New Initial Efficacy Data From Affinity Duchenne® Trial
REGENXBIO’s Research and Development Facility, Maryland, US
REGENXBIO to Host Webcast to Discuss Data from Ph I/II AFFINITY DUCHENNE® Trial